RELAPSE Study

  • Research type

    Research Study

  • Full title

    Prospective Observational Study Evaluating The Treatment Outcomes For Localised Recurrent, Resectable Retroperitoneal Liposarcoma (ReLaPSe)

  • IRAS ID

    354218

  • Contact name

    Samuel Ford

  • Contact email

    samuel.ford@uhb.nhs.uk

  • Sponsor organisation

    Australia and New Zealand Sarcoma Association (ANZSA)

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    Retroperitoneal sarcoma (RPS) is a rare and aggressive type of cancer that develops in the soft tissue of the abdomen. A common challenge with this disease is that even after initial treatment, the cancer can return in the same area. This study, called ReLaPSe, focuses on patients who experience a localized recurrence of a specific type of RPS known as retroperitoneal liposarcoma (LPS). The study aims to evaluate the effectiveness of different treatment approaches, including surgery alone or surgery combined with preoperative radiotherapy (RT), in improving survival and reducing the risk of further recurrence.

    This is a non-randomized, observational study conducted in hospitals in Australia, the UK and an international ‘Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). It will follow approximately 100 patients who have had a previous surgery for their LPS but now have a local recurrence that is still considered operable. The research will examine how well these patients respond to different treatment options and track their long-term outcomes, such as survival rates, quality of life, and the likelihood of further recurrence or complications.

    The study will also validate a predictive tool that helps doctors estimate the prognosis of patients with recurrent RPS. Patients who participate will undergo regular follow-ups for up to five years, including imaging scans and quality-of-life assessments, as is normal practice at present.

    Although there is no direct benefit to participants, this research is expected to provide valuable insights into the best treatment strategies for patients with recurrent retroperitoneal liposarcoma, ultimately helping to improve future care and outcomes.

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    25/WM/0119

  • Date of REC Opinion

    12 Dec 2025

  • REC opinion

    Further Information Favourable Opinion